These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 8377594)
21. Trial of sulfonylurea in combination with insulin in the therapy of diabetes type I and II. Evidence against a primary extrapancreatic receptor effect. Bieger WP; Dlugosch R; Rettenmeier A; Holler HD; Bert H; Schwarz W; Fiehn W; Merkt J; Weicker H Klin Wochenschr; 1984 Jul; 62(13):631-9. PubMed ID: 6434794 [TBL] [Abstract][Full Text] [Related]
22. Type II diabetes mellitus. Edelman SV Adv Intern Med; 1998; 43():449-500. PubMed ID: 9506190 [TBL] [Abstract][Full Text] [Related]
23. Glyburide: a second-generation sulfonylurea hypoglycemic agent. History, chemistry, metabolism, pharmacokinetics, clinical use and adverse effects. Feldman JM Pharmacotherapy; 1985; 5(2):43-62. PubMed ID: 3923453 [TBL] [Abstract][Full Text] [Related]
24. Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus. Yoshihara T; Kumashiro N; Kanazawa Y; Mita T; Sakurai Y; Kawai J; Abe M; Motojima K; Hara K; Yamazaki Y; Kanazawa A; Miwa S; Sato F; Kanno R; Shimizu T; Sakai K; Uchino H; Watada H; Tanaka Y; Kawamori R; Hirose T Endocr J; 2006 Feb; 53(1):67-72. PubMed ID: 16543674 [TBL] [Abstract][Full Text] [Related]
25. Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes. Lam KS; Chow CC; Tan KC; Ma RC; Kong AP; Tong PC; Tsang MW; Chan TM; Tang SC; Lee KK; So WY; Tomlinson B Curr Med Res Opin; 2016 Jun; 32(6):1097-108. PubMed ID: 26933918 [TBL] [Abstract][Full Text] [Related]
26. Insulin-dependent diabetes of pregnancy treated with the combination of sulfonylurea and insulin. Ravina A Isr J Med Sci; 1995 Oct; 31(10):623-5. PubMed ID: 7591687 [No Abstract] [Full Text] [Related]
27. Combination therapy of glibenclamide and insulin in NIDDM patients with secondary failure to oral drugs. Mohan V; Snehalatha C; Ramachandran A; Viswanathan M J Assoc Physicians India; 1990 Aug; 38(8):537-41. PubMed ID: 2123183 [TBL] [Abstract][Full Text] [Related]
28. [Non-insulin-dependent diabetics with secondary failure: insulin therapy at bedtime combined with glibenclamide]. Maiz A; Arteaga A; Klaassen J; Velasco N; Borkosky M; Jiménez M; Acosta AM Rev Med Chil; 1993 Oct; 121(10):1135-41. PubMed ID: 8191117 [TBL] [Abstract][Full Text] [Related]
29. Steatosis and cirrhosis in an obese diabetic. Resolution of fatty liver by fasting. Keeffe EB; Adesman PW; Stenzel P; Palmer RM Dig Dis Sci; 1987 Apr; 32(4):441-5. PubMed ID: 3829884 [TBL] [Abstract][Full Text] [Related]
30. [Combination treatment of insulin dependent elderly diabetics (type II diabetes) with the sulfonylurea compound glibenclamide]. Naurath HJ; Füsgen I Z Gerontol; 1985; 18(5):302-4. PubMed ID: 3934860 [TBL] [Abstract][Full Text] [Related]
31. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted? Standl E; Schnell O Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474 [No Abstract] [Full Text] [Related]
32. Fasting plasma glucose after intensive insulin therapy predicted long-term glycemic control in newly diagnosed type 2 diabetic patients. Liu J; Liu J; Fang D; Liu L; Huang Z; Wan X; Cao X; Li Y Endocr J; 2013; 60(6):725-32. PubMed ID: 23428844 [TBL] [Abstract][Full Text] [Related]
33. Should postprandial hyperglycaemia in prediabetic and type 2 diabetic patients be treated? Charpentier G; Riveline JP; Dardari D; Varroud-Vial M Drugs; 2006; 66(3):273-86. PubMed ID: 16526817 [TBL] [Abstract][Full Text] [Related]
34. The pathology of diabetic hepatitis. Balázs M J Pathol; 1989 Dec; 159(4):351-2. PubMed ID: 2633785 [No Abstract] [Full Text] [Related]
35. [Knack of treatment with oral hypoglycemic drugs in the elderly]. Komatsu M; Hashizume K Nihon Rinsho; 2006 Jan; 64(1):93-8. PubMed ID: 16408454 [TBL] [Abstract][Full Text] [Related]
36. The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects. Kolterman OG; Gray RS; Shapiro G; Scarlett JA; Griffin J; Olefsky JM Diabetes; 1984 Apr; 33(4):346-54. PubMed ID: 6423429 [TBL] [Abstract][Full Text] [Related]
37. Effects of a combination of bedtime intermediate-acting insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to respond to oral hypoglycaemic agents. Krempf M; Godeau T; Ranganathan S; Blanchard P; Ritz P; Charbonnel B Eur J Clin Pharmacol; 1992; 42(3):281-6. PubMed ID: 1577046 [TBL] [Abstract][Full Text] [Related]
38. Add-on treatment with mitiglinide improves residual postprandial hyperglycemia in type 2 diabetic patients receiving the combination therapy with insulin glargine and sitagliptin. Murakami T; Nambu T; Kato T; Matsuda Y; Yonemitsu S; Muro S; Oki S Tohoku J Exp Med; 2015 Apr; 235(4):255-60. PubMed ID: 25810423 [TBL] [Abstract][Full Text] [Related]
39. Glyburide decreases insulin requirement, increases beta-cell response to mixed meal, and does not affect insulin sensitivity: effects of short- and long-term combined treatment in secondary failure to sulfonylurea. Gutniak M; Karlander SG; Efendić S Diabetes Care; 1987; 10(5):545-54. PubMed ID: 2890501 [TBL] [Abstract][Full Text] [Related]
40. Swertisin rich fraction from Enicostema littorale ameliorates hyperglycemia and hyperlipidemia in high-fat fed diet and low dose streptozotacin induced type 2 diabetes mellitus in rats. Mokashi P; Bhatt LK; Khanna A; Pandita N Biomed Pharmacother; 2017 Dec; 96():1427-1437. PubMed ID: 29031588 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]